Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06598943 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Site details revised at 207 of 207 sites Show 1 more changeShow less
    • Site details revised at 207 of 207 sites
  2. Primary completion date changed from estimate of Dec 2027 to Aug 3, 2026 Completion moved earlier from Sep 2028 to Jul 2027 · Eligibility criteria expanded, about 10 words · Site details revised at 41 of 207 sites Show 3 more changesShow less
    • Completion moved earlier from Sep 2028 to Jul 2027
    • Eligibility criteria expanded, about 10 words
    • Site details revised at 41 of 207 sites
  3. Enrollment target: 140 to 143 Site contacts updated at 28 of 207 sitesv24 Show 1 more changeShow less
    • Site contacts updated at 28 of 207 sites
  4. Site contacts updated at 1 of 207 sitesv23
  5. Site details revised at 8 of 207 sitesv22
Show 20 earlier versionsHide 20 earlier versions
  1. Site contacts updated at 1 of 207 sitesv21
  2. Site details revised at 2 of 207 sitesv20
  3. Site details revised at 28 of 207 sitesv19
  4. Site contacts updated at 2 of 207 sitesv18
  5. Site contacts updated at 8 of 207 sitesv17
  6. Site contacts updated at 2 of 207 sitesv16
  7. Site contacts updated at 1 of 207 sitesv15
  8. Study sites: 206 to 207v14
  9. Study sites: 204 to 206v13
  10. Study sites: 203 to 204v12
  11. Study sites: 194 to 203v11
  12. Study sites: 183 to 194v10
  13. Study sites: 175 to 183v9
  14. Study sites: 173 to 175v8
  15. Study sites: 126 to 173v7
  16. Study sites: 83 to 126v6
  17. Study sites: 62 to 83v5
  18. Study sites: 41 to 62v4
  19. Study sites: 28 to 41v3
  20. Trial status: Not Yet Recruiting to Recruiting Study sites: 1 to 28 · Start date changed from estimate of Sep 2024 to Oct 10, 2024v2 Show 2 more changesShow less
    • Study sites: 1 to 28
    • Start date changed from estimate of Sep 2024 to Oct 10, 2024
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
359 trials monitored
See 15 trials at risk
Ulcerative Colitis
587 trials monitored
See 34 trials at risk
The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).
Trial Details
NCT Number NCT06598943
Lead Sponsor Eli Lilly and Company
Conditions Ulcerative Colitis, Ulcerative Colitis Chronic
Enrollment 143 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov